Replies to post #49934 on Biotech Values

[DewDiligence]

>Would appreciate comments on the briefing documents suggestion that overall survival appears to be trending toward final significance<

This means the patients in the Satraplatin arm are living longer than the patients in the control arm, but we don’t yet know whether the difference will be statistically significant.